Didier Landais is appointed 4P-Pharma's CEO to lead the company into a new chapter of its development
5.9.2023 11:30:00 EEST | Business Wire | Press release
4P-Pharma, a pioneering biotechnology company based in Lille and specializing in drug regeneration, is thrilled to achieve a significant milestone in its history. During the latest strategic board meeting, the appointment of Didier Landais as the new CEO of 4P-Pharma was confirmed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905514097/en/
DIDIER LANDAIS CEO - 4P-PHARMA
Founded in 2014 by Revital Rattenbach, 4P-Pharma is entering a new era of its development. On September 1st, 2023, Didier Landais succeeds Revital Rattenbach as CEO of 4P-Pharma. She now holds the position of Executive Chairwoman.
With over 30 years of international experience in the pharma/biotech industry, Didier Landais stands out as an executive leader. His career has been marked by accomplishments in key areas such as research and development, strategy, and business development.
His extensive international experience and proven leadership position Didier Landais as the ideal choice for this strategic function. His past achievements attest to his exceptional ability to guide our teams towards excellence, turning ambitious visions into tangible results. Together, the new executive will combine forces to expedite the company's development."
"We stand on the brink of a pivotal period for 4P-Pharma. The appointment of Didier reinforces our commitment to innovation and growth. His passion for scientific research, coupled with his profound market understanding, will propel forward our mission to transform how we approach health and well-being, driving dynamics of success." stated Revital Rattenbach, 4P-Pharma’s Executive Chairwoman
A strong expertise both in France and internationally, to accelerate the development of 4P-Pharma.
Didier Landais holds a Ph.D. in Molecular and Cellular Biology from the University Louis Pasteur (Strasbourg), as well as an Executive MBA from ESSEC (Paris). He started his career as a researcher and oncology project leader at the Gene Therapy Division of RPR-Gencell (Sanofi) before assuming the role of Director of Business Development and General Manager of Cell Therapy, overseeing the international development of a cancer vaccine at IDM Pharma. He has also held positions including Director of Development at Biotecnol and Chief Business Officer at Genome Profiling. Under his leadership as Global Head of Licensing, Servier concluded several notable agreements, including with Celsius, Oncodesign, and Seal Rock. More recently, he served as COO and CBO at Labgenius Ltd in London."
"Joining 4P-Pharma is a significant step for me. We are developing high-potential molecules that truly transform patients' lives. With the support of Revital and our dedicated teams, I am confident that we will reach new horizons and push the boundaries of innovation even further." expressed Didier Landais, 4P-Pharma’s CEO.
As CEO, Didier Landais holds the responsibility for the company's overall strategy in terms of science, partnerships, and external growth. Revital Rattenbach, now 4P-Pharma’s Executive Chairwoman, remains actively involved in financial consolidation and strategic directions, ensuring the continuity of the company's founding vision.
4P-Pharma remains deeply committed to its partners, investors, and its mission to provide innovative solutions to global health challenges."
ABOUT 4P-PHARMA
4P-Pharma is a clinical stage biotech company, pioneering in drug regeneration, founded in Lille in 2014. We focus on untreated serious diseases with high unmet medical needs, aiming to rapidly deliver effective, regenerated, first-in-class therapies. The company has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver optimized risk adjusted returns. We leverage assets with a short time to market, strong IP position, and regulatory opportunities (emergency use or conditional marketing authorizations) in blue-ocean markets.
Website: https://4p-pharma.com/fr
LinkedIn: https://fr.linkedin.com/company/4p-pharma
Twitter: https://twitter.com/4p_pharma
The only version of the 4P-Pharma press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905514097/en/
Contact information
Press
Najette Chaib – nchaib@beyondcom.fr 06 18 38 11 14
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ExaGrid Achieves Customer Milestone19.2.2026 15:00:00 EET | Press release
ExaGrid®, the leader in Tiered Backup Storage, today announced that over 5,000 customers are actively using its backup storage behind leading backup applications such as Veeam, Commvault, NetBackup, Rubrik, Arcserve, Acronis, SQL Dumps, Oracle RMAN Direct, HYCU, and many other backup applications and utilities. ExaGrid has achieved many milestones, including: +81 NPS score The highest in the backup storage industry 300+ published backup storage customer success stories on its website More than all competitors combined 200+ Gartner Peer Insights reviews With a high rating of 4.8/5 stars 24 Industry Awards in the last 3 years More than any other backup storage provider Over 20 consecutive quarters with positive: Free Cash Flow, P&L and EBITDA “ExaGrid realized that using standard primary storage behind a backup application is not a strong solution, and with any level of retention it’s very expensive as well as vulnerable to security attacks. Inline deduplication appliances such as Dell D
DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy19.2.2026 14:25:00 EET | Press release
The Digital Cooperation Organization (DCO) has announced the launch of the “Stop Online Misinformation: Ctrl+Alt+Delete,” global campaign to counter online misinformation and strengthen trust in the digital economy, calling for coordinated action by governments, media, the private sector, and digital platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218141056/en/ DCO Launches Global “Ctrl+Alt+Delete” Campaign to Combat Online Misinformation and Enhance Trust in Digital Economy - (Photo: AETOSWire) The campaign represents the culmination of a year of sustained multilateral and multistakeholder engagement led by DCO to address misinformation as a growing economic, societal, and trust-related challenge. Underpinned by DCO’s Online Content Integrity initiative, it will roll out in phased stages, anchored in stakeholder pledges and commitments, and advanced through policy dialogue, public engagement, and digital activa
Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme19.2.2026 14:00:00 EET | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Ultra 2, the latest and most advanced member of its rugged T-Rex lineup. As part of the T-Rex family, the T-Rex Ultra 2 is built for uncertainty—designed to remain reliable in conditions where plans, environments, and outcomes are never fully defined. Purpose-built for extreme environments, the T-Rex Ultra 2 combines premium materials, enhanced navigation capabilities, and extended battery life to support athletes and explorers tackling long, complex routes where preparation and reliability matter most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219679075/en/ Amazfit Announces the T-Rex Ultra 2: a Titanium GPS Watch Engineered for the Extreme “With the T-Rex Ultra 2, we focused on building a watch for people who rely on navigation, endurance, and on-watch decision-making in demanding environments,” said Scott Shepley, Head o
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 13:00:00 EET | Press release
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as a one‑time treatment approach,” stated Yuxuan Wu, M.D., Founder and CEO of YolTech Therapeutics. “Equally encouraging is the favorable safety profile we have seen to date, which
Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 12:15:00 EET | Press release
Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Molly Gatford, Senior Research Analyst, Juniper Research, said:“
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom